Related Experiment Video
Updated: Jul 27, 2025
08:50
Scalable Biomanufacturing Workflow to Produce and Isolate Natural Killer Cell-Derived Extracellular Vesicle-Based Cancer Biotherapeutics
Published on: August 16, 2024
782
Engineered Extracellular Vesicles with Compound-Induced Cargo Delivery to Solid Tumors
1Department of Biochemistry, School of Medicine, Daegu Catholic University, Daegu 42472, Republic of Korea.
International Journal of Molecular Sciences
|June 10, 2023
Summary
Researchers developed a novel system to deliver therapeutic cargo using extracellular vesicles (EVs) and a small molecule-induced protein interaction. This method enhances EV delivery to refractory cancer cells, offering new therapeutic possibilities for difficult-to-treat cancers.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- Efficient delivery of therapeutic agents into target cells is a significant challenge in medicine.
- Extracellular vesicles (EVs) show promise as delivery vehicles, but improved tools are needed for targeting cancer cells.
- Refractory cancers, including triple-negative breast, non-small cell lung, and pancreatic cancers, require innovative therapeutic strategies.
Purpose of the Study:
- To develop a novel, inducible system for delivering specific cargo via extracellular vesicles (EVs) to refractory cancer cells.
- To utilize a small molecule-induced protein-protein interaction (PPI) to enhance EV-mediated cargo delivery.
- To demonstrate the functional delivery of EVs loaded with therapeutic cargo to various hard-to-treat cancer cell types.
Main Methods:
- Engineered an inducible interaction system using the FKBP12-rapamycin-binding protein (FRB) domain and FK506 binding protein (FKBP).
- Fused CD9, an EV protein, to the FRB domain and linked specific cargo to FKBP.
- Utilized rapamycin to induce protein-protein interactions, recruiting cargo to EVs for subsequent delivery.
Main Results:
- Successfully demonstrated the recruitment of validated cargo to EVs through the inducible FKBP-FRB interaction system.
- Showcased functional delivery of these engineered EVs to refractory cancer cells, including triple-negative breast cancer, non-small cell lung cancer, and pancreatic cancer cells.
- Validated the efficacy of the small molecule-induced trafficking system for therapeutic cargo delivery.
Conclusions:
- The developed reversible PPI-driven system provides a promising new method for enhancing EV-mediated drug delivery.
- This functional delivery system offers novel therapeutic possibilities for combating refractory cancers.
- The inducible nature of the system allows for controlled cargo loading and targeted delivery to cancer cells.
